AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29193014 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention to correct student misperceptions of the profitability of higher education.
Number of subjects: 9000
Study 29193014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 9000
Study 29193014 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention.
Number of subjects: 9000
Study 26553376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV)
Number of subjects: 200
Study 26553376 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 200
Study 25568560 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules containing 500 mg of powdered sumac fruits, three times a day for one month
Number of subjects: 72
Study 25568560 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 72
Study 22677302 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/ml diclofenac sodium HPβCD (i.m.)
Number of subjects: 42
Study 22677302 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/ml diclofenac sodium HPβCD (s.c.)
Number of subjects: 42
Study 22677302 — intervention group
Group type: EXPERIMENTAL
Intervention: 25, 50, or 75 mg/ml diclofenac sodium HPβCD (s.c.)
Number of subjects: 42
Study 22677302 — intervention group
Group type: COMPARATOR
Intervention: Voltaren® 75 mg/3 ml (i.m.)
Number of subjects: 42
Study 20194850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap 45 (radiotherapy 45 Gy/25 fractions with concurrent capecitabine 800 mg/m² twice daily 5 days per week)
Number of subjects: 598
Study 20194850 — intervention group
Group type: COMPARATOR
Intervention: Capox 50 (radiotherapy 50 Gy/25 fractions with capecitabine 800 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly)
Number of subjects: 598
Study 18071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 314
Study 18071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 314
Study 18071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants plus counseling
Number of subjects: 314
Study 18071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 314
Study 18071094 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 314
Study 18071094 — intervention group
Group type: COMPARATOR
Intervention: Treatment offered
Number of subjects: 314
Study 15900097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose FK506
Number of subjects: 34
Study 15900097 — intervention group
Group type: COMPARATOR
Intervention: Control (no FK506)
Number of subjects: 34
Study 11988250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen prophylaxis for patent ductus arteriosus
Number of subjects: 0
Study 9457018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 249
Study 9457018 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear/Biteplane
Number of subjects: 249
Study 9457018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 249
Study 7608428 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatebradine (5 mg twice a day)
Number of subjects: 124
Study 7608428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 1700580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylsulfoxide
Number of subjects: 0
Study 1700580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosampolysulphate
Number of subjects: 0
Study 342622 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent whole‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Number of subjects: 208
Study 342622 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent split‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Number of subjects: 208
Study 342622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 342622 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐virus vaccine
Number of subjects: 208
Study 342622 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 208
Study 6459776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.125 mg
Number of subjects: 10
Study 6459776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.25 mg
Number of subjects: 10
Study 6459776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.5 mg
Number of subjects: 10
Study 6459776 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 5 mg
Number of subjects: 10
Study 6459776 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 31500629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract
Number of subjects: 0
Study 31500629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30227910 — intervention group
Group type: EXPERIMENTAL
Intervention: LARC initiation within 90 days after abortion in KPNC facilities
Number of subjects: 0
Study 30227910 — intervention group
Group type: COMPARATOR
Intervention: LARC initiation within 90 days after abortion in contracted facilities
Number of subjects: 0
Study 30227910 — intervention group
Group type: COMPARATOR
Intervention: Short-acting or no contraception initiation
Number of subjects: 0
Study 30227910 — intervention group
Group type: COMPARATOR
Intervention: No contraception initiation
Number of subjects: 0
Study 26969812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 26969812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 25163995 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical Concentration Training with Pepe (MusiKo mit Pepe)
Number of subjects: 108
Study 25163995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 22343090 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 400
Study 22343090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 400
Study 22343090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 22343090 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (escitalopram or amitriptyline)
Number of subjects: 400
Study 20120421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivité Skin Care System
Number of subjects: 36
Study 20120421 — intervention group
Group type: COMPARATOR
Intervention: Cetaphil moisturizing regimen
Number of subjects: 36
Study 17324679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (six 1-hour sessions)
Number of subjects: 42
Study 17324679 — intervention group
Group type: COMPARATOR
Intervention: Guided Visual Imagery (two 1-hour sessions)
Number of subjects: 42
Study 16003622 — intervention group
Group type: EXPERIMENTAL
Intervention: Handpiece usage during surgical exodontia procedures
Number of subjects: 100
Study 16003622 — intervention group
Group type: COMPARATOR
Intervention: Manufacturers' recommendations for handpiece use time cycles
Number of subjects: 100
Study 16003622 — intervention group
Group type: COMPARATOR
Intervention: Operator experience
Number of subjects: 100
Study 12143093 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a separator
Number of subjects: 142
Study 12143093 — intervention group
Group type: COMPARATOR
Intervention: Upper alginate impression
Number of subjects: 142
Study 12143093 — intervention group
Group type: COMPARATOR
Intervention: Separator placement
Number of subjects: 142
Study 12143093 — intervention group
Group type: COMPARATOR
Intervention: Band placement
Number of subjects: 142
Study 12143093 — intervention group
Group type: COMPARATOR
Intervention: Archwire adjustment
Number of subjects: 142
Study 10421307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 10421307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study 7796781 — intervention group
Group type: EXPERIMENTAL
Intervention: AcOH (olive oil plus 1 g acetic acid in the form of vinegar)
Number of subjects: 5
Study 7796781 — intervention group
Group type: EXPERIMENTAL
Intervention: AcOH + Bread (olive oil plus 1 g acetic acid in the form of vinegar followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5
Study 7796781 — intervention group
Group type: EXPERIMENTAL
Intervention: AcNa (olive oil plus sodium acetate in the form of vinegar neutralized to pH 6.0)
Number of subjects: 5
Study 7796781 — intervention group
Group type: COMPARATOR
Intervention: Blank + Bread (olive oil without vinegar followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5
Study 7796781 — intervention group
Group type: EXPERIMENTAL
Intervention: AcNa + Bread (olive oil plus sodium acetate followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5
Study 2368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 40 mg/kg (Group 1)
Number of subjects: 339
Study 2368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg/kg (Group 2)
Number of subjects: 339
Study 2368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.005 mg/kg (both groups)
Number of subjects: 339
Study 2368891 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg (both groups)
Number of subjects: 339
Study 2368891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (both groups)
Number of subjects: 339
Study 97705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthusiastic messages of drug effects
Number of subjects: 0
Study 97705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental staff perceived as friendly and supportive
Number of subjects: 0
Study 29336900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 99mTc-MIBI + NC (group I)
Number of subjects: 40
Study 29336900 — intervention group
Group type: COMPARATOR
Intervention: Low-dose 99mTc-MIBI (group II)
Number of subjects: 40
Study 29336900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27008092 — intervention group
Group type: EXPERIMENTAL
Intervention: Global medium
Number of subjects: 73
Study 27008092 — intervention group
Group type: COMPARATOR
Intervention: Single Step Medium (SSM)
Number of subjects: 73
Study 24356394 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 2000
Study 24356394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin α
Number of subjects: 2000
Study 24356394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 23517248 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIRO trial patients
Number of subjects: 1946
Study 23517248 — intervention group
Group type: COMPARATOR
Intervention: Non-eligible non-trial patients
Number of subjects: 1946
Study 20101012 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (n = 54)
Number of subjects: 155
Study 20101012 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (n = 52)
Number of subjects: 155
Study 20101012 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly balance and tone training (control group, n = 49)
Number of subjects: 155
Study 20101012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both resistance training groups
Number of subjects: 155
Study 17762913 — intervention group
Group type: EXPERIMENTAL
Intervention: rimexolone 1% one eye drop every 4 h (n = 44 eyes)
Number of subjects: 80
Study 17762913 — intervention group
Group type: COMPARATOR
Intervention: prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes)
Number of subjects: 80
Study 17762913 — intervention group
Group type: EXPERIMENTAL
Intervention: rimexolone 1%
Number of subjects: 80
Study 17762913 — intervention group
Group type: COMPARATOR
Intervention: prednisolone acetate 1%
Number of subjects: 80
Study 17762913 — intervention group
Group type: EXPERIMENTAL
Intervention: rimexolone 1% and prednisolone acetate 1%
Number of subjects: 80
Study 16873556 — intervention group
Group type: EXPERIMENTAL
Intervention: DFA analysis in nondiabetic subjects; DFA exponent alpha = 1.25 +/- 0.29
Number of subjects: 27
Study 16873556 — intervention group
Group type: COMPARATOR
Intervention: DFA analysis in diabetic patients; DFA exponent alpha = 1.65 +/- 0.30
Number of subjects: 27
Study 12828584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline treatment in group C (n=5)
Number of subjects: 25
Study 12828584 — intervention group
Group type: COMPARATOR
Intervention: Group B (n=8)
Number of subjects: 25
Study 12828584 — intervention group
Group type: COMPARATOR
Intervention: Group C (n=5)
Number of subjects: 25
Study 10731502 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg/d for 28 days)
Number of subjects: 0
Study 10731502 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0
Study 10731502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation
Number of subjects: 0
Study 10731502 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 9180204 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone plus proguanil
Number of subjects: 154
Study 9180204 — intervention group
Group type: COMPARATOR
Intervention: Quinine plus tetracycline
Number of subjects: 154
Study 7506169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg orally, twice daily)
Number of subjects: 180
Study 7506169 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20mg orally, once daily)
Number of subjects: 180
Study 7506169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100mg orally, twice daily)
Number of subjects: 180
Study 7506169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 3775328 — intervention group
Group type: COMPARATOR
Intervention: Load of 0 kg
Number of subjects: 9
Study 3775328 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 10 kg
Number of subjects: 9
Study 3775328 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 15 kg
Number of subjects: 9
Study 3775328 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 20 kg
Number of subjects: 9
Study 31647379 — intervention group
Group type: EXPERIMENTAL
Intervention: Redundant condition (both visual and verbal instructions)
Number of subjects: 0
Study 31647379 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition (instructions shown using arrow symbols)
Number of subjects: 0
Study 31647379 — intervention group
Group type: COMPARATOR
Intervention: Verbal condition (instructions given orally)
Number of subjects: 0
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 1217
Study 29562258 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 1217
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glasgow coma scale
Number of subjects: 1217
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood urea-nitrogen
Number of subjects: 1217
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidotic base-excess
Number of subjects: 1217
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of shock
Number of subjects: 1217
Study 29562258 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of coma
Number of subjects: 1217
Study 27233673 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warm-up in a VRSS
Number of subjects: 20
Study 27233673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warm-up)
Number of subjects: 20
Study 24238032 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.2 mg·kg(‐1)
Number of subjects: 80
Study 24238032 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 0.5 mg·kg(‐1)
Number of subjects: 80
Study 24238032 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 80
Study 24238032 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 80
Study 22023655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite allergen-impermeable mattress covers
Number of subjects: 1282
Study 22023655 — intervention group
Group type: COMPARATOR
Intervention: Placebo mattress covers
Number of subjects: 1282
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (58 mmol . L(‐1) . d(‐1))
Number of subjects: 58
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (170 mmol . L(‐1) . d(‐1))
Number of subjects: 58
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentrations after upright posture
Number of subjects: 58
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentrations when supine
Number of subjects: 58
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary aldosterone excretion rates
Number of subjects: 58
Study 20007307 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 3 measurements (blood pressure, body weight, urinary volume, creatinine, serum sodium and potassium)
Number of subjects: 58
Study 18797348 — intervention group
Group type: EXPERIMENTAL
Intervention: Met allele carriers
Number of subjects: 96
Study 18797348 — intervention group
Group type: COMPARATOR
Intervention: Val/Val homozygotes
Number of subjects: 96
Study 18797348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left and bilateral infarctions
Number of subjects: 96
Study 15699222 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing targeted sedentary behaviors by 25‐50%
Number of subjects: 16
Study 15699222 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing targeted sedentary behaviors by 25‐50%
Number of subjects: 16
Study 14644671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer education sessions (20 bi-weekly sessions over 1 year and quarterly booster sessions for 2 years)
Number of subjects: 594
Study 14644671 — intervention group
Group type: COMPARATOR
Intervention: Control group (received brochures on basic lead prevention strategies)
Number of subjects: 594
Study 14644671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer education
Number of subjects: 594
Study 10820694 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication interventions (three styles)
Number of subjects: 0
Study 10820694 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 0
Study 10820694 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videos
Number of subjects: 0
Study 10820694 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational activities
Number of subjects: 0
Study 10820694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interacting with patients with caring and concern
Number of subjects: 0
Study 10820694 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 8899083 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 25
Study 8899083 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 75 mg
Number of subjects: 25
Study 8899083 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 1508355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-fentanyl preheated to 37 degrees C (n = 25)
Number of subjects: 50
Study 1508355 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine-fentanyl at room temperature (20 degrees C) (n = 25)
Number of subjects: 50
Study 6828237 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 210
Study 6828237 — intervention group
Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 210
Study 6828237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iohexol and metrizoate
Number of subjects: 210
Study 31330149 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g sucrose
Number of subjects: 13
Study 31330149 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g sucrose with 160mg of vitamin C
Number of subjects: 13
Study 31330149 — intervention group
Group type: COMPARATOR
Intervention: 300ml water (control)
Number of subjects: 13
Study 30145934 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CTA) plus standard care
Number of subjects: 4146
Study 30145934 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 4146
Study 26789727 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1-mutated transcripts present after second chemotherapy cycle
Number of subjects: 346
Study 26789727 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease status determined by NPM1-mutated transcripts
Number of subjects: 346
Study 26789727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monitoring of minimal residual disease
Number of subjects: 346
Study 26789727 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of NPM1 mutations at relapse
Number of subjects: 346
Study 24678999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1691
Study 24678999 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator therapy alone
Number of subjects: 1691
Study 24678999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without left bundle-branch block
Number of subjects: 1691
Study 22913215 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of L-arginine for 3 months
Number of subjects: 60
Study 22913215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22913215 — intervention group
Group type: COMPARATOR
Intervention: Control (20 healthy lean subjects)
Number of subjects: 60
Study 20948193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high simple carbohydrate diet (SCHO)
Number of subjects: 47
Study 20948193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high complex carbohydrate diet (CCHO)
Number of subjects: 47
Study 20948193 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 47
Study 17878469 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 17878469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Number of subjects: 0
Study 17878469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures
Number of subjects: 0